Annexon (ANNX) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

ANNX Annexon

Watchlist

6.890
+0.750+12.21%

Close Oct 8 16:00 ET

6.898
+0.008+0.12%

Post 20:01 ET

727.96MMarket Cap-5694P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Annexon Added to Q4 2024 Tactical Ideas List at Wells Fargo
TipRanksOct 1 07:36 ET
Wells Fargo Maintains Annexon(ANNX.US) With Buy Rating, Maintains Target Price $14
Moomoo NewsOct 1 07:31 ET · Ratings
Buy Rating Affirmed for Annexon Biosciences Amidst Promising Clinical Developments and Market Potential
TipRanksOct 1 06:56 ET · Ratings
Annexon EVP Sells Shares Worth Over $30,000
InvestingSep 20 16:34 ET
Express News | Cantor Fitzgerald Reiterates Overweight on Annexon
BenzingaSep 9 12:53 ET
Annexon Presents Phase 2 ARCHER Data On Protection Of Vision And Photoreceptors With ANX007 In GA At The Retina Society 57th Annual Meeting And 24th Euretina Congress
BenzingaSep 9 08:03 ET

Comments

Trytosaveabit

9 hours ago

Time to start watching for data release again! Hehehe!

$Annexon (ANNX.US)$ Looking for this soon.
((((((. ANX1502 in CAD: POC trial evaluating the pharmacodynamics and efficacy of an oral tablet formulation in CAD anticipated to provide initial data in the fourth quarter of 2024 )))))

Trytosaveabit

Aug 13 04:34

Note the dates!

$Annexon (ANNX.US)$ Key Anticipated Milestones for Flagship Programs
*ANX005 in GBS: Initial topline data from RWE comparability protocol with IGOS now expected by year-end 2024 to support a planned BLA submission in the first half of 2025
*ANX1502 in CAD: POC trial evaluating the pharmacodynamics and efficacy of an oral tablet formulation in CAD anticipated to provide initial data in the fourth quarter of 2024

Jaguar8

Jul 11 17:10

NEWS

$Annexon (ANNX.US)$
Annexon to Present Additional Phase 2 Data Showing Preservation of Visual Function and Structure by ANX007 in Geographic Atrophy at the 42nd ASRS Annual Scientific Meeting
Annexon will present additional data from its Phase 2 ARCHER trial on ANX007 at the 42nd ASRS Annual Scientific Meeting in Stockholm, Sweden from July 17-20, 2024. The presentations will highlight the protective effects of ANX007 on visual acuity and anatomical measures in patients with geographic atroph...

Trytosaveabit

Jun 25 16:07

$Annexon (ANNX.US)$ Did anyone remember to be watching for this? I told Y’all on the 18th to be looking! Hehehe

Trytosaveabit

Jun 25 16:05

Update

$Annexon (ANNX.US)$ Reuters· 5 mins ago
Annexon Presented Additional Positive Phase 3 Results for Anx005 C1Q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 Pns Annual Meeting

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

No Data

ANNX Annexon

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target